Evaluation of eleven immunochromatographic assays for SARS-CoV-2 detection: investigating the dengue cross-reaction

Carregando...
Imagem de Miniatura
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.64, article ID e63, 8p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
COVID-19 disease is spread worldwide and diagnostic techniques have been studied in order to contain the pandemic. Immunochromatographic (IC) assays are feasible and a low-cost alternative especially in low and middle-income countries, which lack structure to perform certain diagnostic techniques. Here we evaluate the sensitivity and specificity of eleven different IC tests in 145 serum samples from confirmed cases of COVID-19 using RT-PCR and 100 negative serum samples from blood donors collected in February 2019. We also evaluated the cross-reactivity with dengue using 20 serum samples from patients with confirmed diagnosis for dengue collected in early 2019 through four different tests. We found high sensitivity (92%), specificity (100%) and an almost perfect agreement (Kappa 0.92) of IC assay, especially when we evaluated IgG and IgM combined after 10 days from the onset of symptoms with RT-PCR. However, we detected cross-reactivity between dengue and COVID-19 mainly with IgM antibodies (5 to 20% of cross-reaction) and demonstrated the need for better studies about diagnostic techniques for these diseases.
Palavras-chave
IC assays, COVID-19, Dengue, Serology
Referências
  1. Brasil. Ministerio da Saude, 2020, B EPIDEMIOLOGICO, V51, P1
  2. Chen ZH, 2020, ANAL CHEM, V92, P7226, DOI 10.1021/acs.analchem.0c00784
  3. Conte DD, 2021, BRAZ J MICROBIOL, V52, P1161, DOI 10.1007/s42770-021-00498-z
  4. De Almeida SM, 2021, MED PRIN PRACT, V30, P385, DOI 10.1159/000516776
  5. Fernandes Q, 2017, LIFE SCI, V178, P100, DOI 10.1016/j.lfs.2017.03.025
  6. Harapan H, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2161
  7. Hasoksuz M, 2020, TURK J MED SCI, V50, P549, DOI 10.3906/sag-2004-127
  8. Hsieh WY, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11101760
  9. Imai K, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104393
  10. Joob B, 2020, J AM ACAD DERMATOL, V82, pE177, DOI 10.1016/j.jaad.2020.03.036
  11. LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
  12. Lee K, 2009, GLOB INST, P1
  13. Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
  14. Liu XM, 2020, EMERG MICROBES INFEC, V9, P1269, DOI 10.1080/22221751.2020.1773324
  15. Lorenz C, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101659
  16. McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
  17. Mohit E, 2021, EXPERT REV CLIN IMMU, V17, P573, DOI 10.1080/1744666X.2021.1908886
  18. Moulahoum H, 2021, TALANTA, V222, DOI 10.1016/j.talanta.2020.121534
  19. Oliveira BA, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062044, 10.1590/s1678-9946202062044]
  20. Pan YB, 2020, J INFECTION, V81, pE28, DOI 10.1016/j.jinf.2020.03.051
  21. Parikh R, 2008, INDIAN J OPHTHALMOL, V56, P45, DOI 10.4103/0301-4738.37595
  22. Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
  23. Ridwan R, 2020, TROP DOCT, V50, P270, DOI 10.1177/0049475520936874
  24. Rivera-Olivero IA, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.787987
  25. Shaffaf T, 2021, BIOENGINEERING-BASEL, V8, DOI 10.3390/bioengineering8050054
  26. Tahamtan A, 2020, EXPERT REV MOL DIAGN, V20, P453, DOI 10.1080/14737159.2020.1757437
  27. World Health Organization, COR DIS COVID 2019 S
  28. Yan G, 2020, LANCET INFECT DIS, V20, P536, DOI 10.1016/S1473-3099(20)30158-4
  29. Yan Y, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2106
  30. Zhang ZL, 2021, J MED VIROL, V93, P366, DOI 10.1002/jmv.26211